Since other autoimmune diseases, including rheumatoid arthritis, are also associated with abnormalities in the IGF-I/IGF-IR pathway (61, 69), the potential therapeutic effects of IGF-IR inhibition may yield advances in treatments of those conditions as well. The gene discussed is IGF1R; the disease is autoimmune disease.